Ajanta Pharma Limited (NSE: AJANTAPHARMA): Q3 FY23 Results Out; Total Income Rises 17% YoY

Ajanta Pharma Limited (NSE: AJANTAPHARMA) is an Indian pharmaceutical company that specializes in the production and distribution of generic drugs. The company has reported its financial results for the third quarter (Q3) of fiscal year 2023 (FY23) and for the first nine months (9M) of the fiscal year. The revenue from operations in Q3FY23 was Rs 972 crore, an increase of 16% from the previous quarter (Rs 838 crore). The revenue from operations for the first nine months of the fiscal year was Rs 2,861 crore, up 16% from the previous year (Rs 2,471 crore).

The EBITDA in Q3FY23 was Rs 170 crore, a decrease of 29% from the previous quarter (Rs 240 crore). The EBITDA margin was 17% of revenue from operations. The adjusted EBITDA, after adjusting for the forex derivative loss, was Rs 207 crore, a decrease of 14% from the previous quarter (Rs 240 crore). The adjusted EBITDA margin was 21% of revenue from operations.

For the first nine months of the fiscal year, the EBITDA was Rs 588 crore, a decrease of 19% from the previous year (Rs 723 crore). The EBITDA margin was 21% of revenue from operations. The adjusted EBITDA, after adjusting for the forex derivative loss, was Rs 631 crore, a decrease of 13% from the previous year (Rs 723 crore). The adjusted EBITDA margin was 22% of revenue from operations. The Profit After Tax in Q3FY23 was Rs 135 crore, a decrease of 30% from the previous quarter (Rs 192 crore). The PAT margin was 14% of revenue from operations. For the first nine months of the fiscal year, the PAT was Rs 466 crore, a decrease of 17% from the previous year (Rs 561 crore). The PAT margin was 16% of revenue from operations. The company has reported an EPS of Rs. 10.50 for the period ended December 31, 2022, a decrease of 14% from the previous quarter (Rs. 12.22). The EPS has decreased by 29% compared to the same period in the previous year (Rs. 14.77).

Ajanta Pharma Ltd reported a 16% increase in revenue from operations in Q3FY23 and 9MFY23, but a decrease in EBITDA and PAT compared to the same period in the previous year. The adjusted EBITDA margin was slightly higher, indicating improved operational efficiency.